International Journal of
Advance in Molecular Engineering

Volume 1, Issue 1, 2023
January-June
DOI (Journal): 10.37591/IJAME

https://journals.stmjournals.com/ijame/

Review IJAME

Revolutionizing Anti-Allergy Medications: A Comprehensive Review of Target Discovery and Medicinal Chemistry

Neha Sahu[1,*], Rizwan Arif[2]

Abstract

Above the past few decades, the prevalence of allergy illnesses has been steadily rising, impacting 20–30% of the world's population. Multiple targets are involved in allergic reactions to infections of the skin, digestive tract, and respiratory system. Developing medications with a good curative efficacy and minimal side effects while utilizing novel multi-targets and processes in accordance with the clinical features of various allergic populations and allergens is the primary challenge facing research on anti-allergy therapies. The knowledge on possible therapeutic targets and the medicinal chemistry of synthetic anti-allergy small molecules are the main topics of this review. With reference to leukotriene production, wascium channel blockers, inhibitors of Th2 cytokines, histamine-1/4 receptor antagonists, and leukotrienes, the structure-activity relationship and the mechanism of compound-target interaction were highlighted. The investigation of chemical scaffold optimization and modification for various lead compounds, which is compiled in this review, should serve as a valuable resource for the drug design of related and promising research, such as allergy, in addition to improving the success rate and effectiveness of virtual screening for antiallergic drugs.

Keywords: Allergic reactions, medications, medicinal chemistry, antiallergic drugs, anti-allergy therapies, synthetic anti-allergy small molecules

INTRODUCTION

When an immune system is reposed to the same allergen, it can cause tissue damage or a malfunctioning reaction, which is commonly referred to as allergy. About 20–30% of people worldwide suffer from allergic rhinitis, asthma, atopic dermatitis, food allergies, and allergic illnesses that have become more common during the past few decades. Owing to the rise in demand, scientists have concentrated on creating sophisticated and practical pharmaceutical substances from biological and chemical sources to effectively treat various allergy types. Anti-allergy medications are now at the forefront of the pharmaceutical industry due to the rising demand and use of these compounds. Over the projection period of 2021 to 2029, the anti-allergy medications market is expected to rise fast due to an increase in demand and usage in recent years. One important mediator of localized hypersensitivity reactions is histamine. In terms of medicine, a diverse array of effector cells and mediators are involved in allergic reactions. A variety of clinical symptoms, including peptic ulcer, diarrhea, allergic dermatitis, asthma, allergic rhinitis, and pain in the respiratory, digestive, and cardiovascular systems, can be brought on by allergies. Antihistamines function by attaching themselves to one of the four recognized histamine receptors [1].

***Author for Correspondence**
Neha Sahu
E-mail: nehasahu082018@gmail.com

[1]Research Scholar, Department of Chemistry School of Basic & amp; Applied Sciences, Lingaya's Vidyapeeth, Faridabad, Haryana, India
[2]Assistant Professor, Department of Chemistry School of Basic & amp; Applied Sciences, Lingaya's Vidyapeeth, Faridabad, Haryana, India

Received Date: December 15, 2023
Accepted Date: December 29, 2023
Published Date: January 19, 2024

Citation: Neha Sahu, Rizwan Arif. Revolutionizing Anti-Allergy Medications: A Comprehensive Review of Target Discovery and Medicinal Chemistry. International Journal of Advance in Molecular Engineering. 2023; 1(1): 49–54p.

LITERATURE

The skin, lungs, digestive tract, and cardiovascular systems are all involved in the quickly evolving multisystem process known as an allergic reaction. Cardiopulmonary problems, advanced age, and delayed epinephrine administration are risk factors for severe anaphylaxis. The most important strategy to manage allergies is to avoid contact, however this does not completely remove the risk of allergies. The primary goals of today's therapeutic medications are to address typical allergic reaction features, and the major goals of treatment are to suppress immune system abnormalities and prevent allergic inflammatory reactions [2].

Allergies Caused by Fungi

After pollens and mites, fungi are thought to be the third most common cause of respiratory illnesses. Patients who are allergic to fungi tend to have more severe asthma and a poorer prognosis. Following a patient's visit to a winery, asthmatic symptoms were noted in 1726, marking the first documented incidence of fungus asthma. Since then, a number of writers have connected fungus to symptoms associated with respiratory allergies. Because fungal allergens are so common, they may also be to blame for occupational asthma and contact dermatitis, which can afflict people in farming, gardening, forestry, and other professions. There is still more to learn about the function that fungi play in the emergence of allergy disorders. The fact that fungal allergens are present in the atmosphere year-round in both indoor and outdoor settings is the primary reason why fungi have not historically been thought of as a potential cause of respiratory allergies, including asthma [3].

Dust Mite Allergies in The Home

The most significant indoor allergen elicitors are HDMs, which are present practically everywhere. Up to 20% of people in locations where mites are common are hypersensitive, making up roughly 50% of allergy sufferers. Atopic dermatitis, asthma, and other severe and persistent allergic reactions can all be brought on by HDMs [4].

The two-house dust mite species, D. pteronyssinus and D. farinae, are common in temperate climates. Most of their allergens exhibit high levels of cross-reactivity and strong sequence homology (80–85%). The allergies of D. pteronyssinus and B. tropicalis will be the subject of this section because B. tropicalis is a significant source of sensitizing allergens linked to rhinitis and asthma in tropical climates [5].

Allergens Originating from Animals

An overview of the allergen molecules derived from animals that have been officially recognized by the WHO/IUIS Allergen Nomenclature Sub-Committee is given in this section. The allergen molecules have been categorized based on the common sources of allergens, which include guinea pigs, dogs, cats, horses, cows, mice, rats, hamsters, and rabbits. Patients with allergies may experience symptoms when they are directly exposed to these animals, such as when they own animals or when they are at work. Furthermore, meeting people who are wearing allergens from their clothing or the indoor environments of public buildings, where dust settles and allergens gather, can also result in indirect exposure to animal allergens [6].

The most popular home pets are dogs and cats. Cat allergy affects up to 20% of the population in some areas, such as Scandinavia and Russia, where it is very common. Cat allergens can be found in dander, hair, skin, saliva, serum, and urine, and sensitivity to these allergens is a significant risk factor for asthma [7].

Potency That Sensitizes

The mouse local lymph node assay has been used to evaluate the sensitizing potential of octocrylene. Octocrylene's EC3 value of 7.7%, or 0.21 M, indicated that it was a moderate sensitizer. It has been demonstrated that this substance reacts, at room temperature, with the amines benzylamine and Nα-acetyl-L-lysine methyl ester by an initial Michael-type addition and a subsequent reaction sequence that

is like a retro-aldol reaction. The explanation for octocrylene's capacity to induce contact allergy has been proposed to be its reactivity towards amines [8].

Patch Testing Among Patient Groups

There are no studies where patients who are suspected of having allergic contact dermatitis have routinely undergone patch tests with octocrylene (unselected). Nonetheless, a few researchers have shared their findings from testing octocrylene in cohorts of patients, such as those with a history of photosensitivity, exposed site dermatitis, sunscreen intolerance, or suspected adverse reactions to ketoprofen gel [9].

Climate Change's Impact on the Rise in Allergic Disorders

The recent study also shown how variations in the climate or environment might affect the metaexposome and cause an increase in allergy disorders. In fact, during the past few decades, human exposure to processed foods and antibiotics has increased along with human exposure to anthropogenic contaminants in the soil, air, and water. Their exposure to healthy microorganisms also dropped at the same time [10].

eBook on Oxygen Measurement

A Simple Guide to Dissolved Oxygen Measurement This booklet provides concise, easily understood instruction on the fundamentals of measuring dissolved oxygen (DO). Get the most recent version here.Since preindustrial times, humans have caused an increase in temperature of about 1°C, which has led to an increase in global warming over time and unprecedented repercussions[11].

The fields of allergy and immunology science converge at a critical juncture when preserving human health, particularly that of high-risk groups, children, expectant mothers, and Indigenous Australians, is vital to safeguarding planetary biodiversity. To lessen exposure to smoke and pollution, few buildings in underprivileged areas have air conditioning or sufficient ventilation. Playing in schoolyards for most of the day exposes kids to dust and pollen, which raises their risk of getting allergic rhinitis [12].

The Microbiome's Function in Allergies

The microbiome's contribution to the disruption of the epidermal barrier is the next topic. For example, in specific regions of the skin of sick people, Staphylococcus aureus secretes toxins and proteases, which activates TH2 cytokines like IL-4. The bacteria Clostridium difficile, Escherichia coli, Haemophilus, and Streptococcus species are also linked to the allergic condition [13].

Research has also demonstrated that the makeup of cutaneous microbes influences a newborn's adaptive immunity to commensals. Any changes to these gut bacteria have an impact on health because they stimulate intestinal IL-10-secreting B cells for immunological tolerance and mucosal homeostasis. Moreover, infections with respiratory viruses, such as respiratory syncytial virus (RSV), may raise the risk of asthma in younger infants whose lungs are still developing. A third of infants hospitalized for bronchiolitis go on to develop asthma later, according to sufficient data [14].

Allergy Treatment and Prevention

Allergies may be avoided by early epithelial barrier repair and allergen exposure. Furthermore, limiting exposure to air contaminants (such as pollen) may help avoid aggravated allergic reactions. However, by encouraging Treg cells to activate tolerogenic pathways, introducing a varied diet during infancy reduces the incidence of allergies [15].

Global recommendations for food introduction have been influenced by the Learning Early About Peanut (LEAP) allergy, which shown that introducing peanuts into an infant's diet at an early age avoided allergies later. Similarly, moisturizers that replicate the physiological pH and lipid composition of skin are being investigated by researchers as a potential means of reducing the incidence of allergies brought on by damaged skin [16].

Using filters to reduce pollen exposure and minimizing emissions from fossil fuels are two further preventative measures. In this sense, reducing indoor air pollution may be aided by monitoring apps that offer real-time information on pollutants and providing high-efficiency particulate air (HEPA) filters to underprivileged populations in developing countries [17].

Treatment options include a plethora of anti-allergy medications and allergen-specific immunotherapy. Among them are Janus kinase (JAK) inhibitors and antihistamines. Omalizumab was approved by the US Food and Drug Administration (FDA) [18],

A monoclonal antibody in 2003 to treat asthma. Twelve years later, mepolizumab, another biologic, was also approved for the treatment of asthma. Many additional biologics, such as the IL-4R inhibitor dupilumab, that target cytokines implicated in the allergy pathway will be ready for clinical usage by 2022. A phase III clinical trial is also underway for an antibody cocktail consisting of two human monoclonal IgG antibodies [19].

TECHNICAL PROGRAMS

Apart from continuous clinical studies, technological advancements are gradually changing clinical practice and managing FA. The COVID-19 pandemic has expedited the integration of remote communication technology into clinics, with numerous medical practitioners currently providing telehealth consultations.106–108 In a similar vein, allergy sufferers may now locate allergen-free meals using a range of phone apps. Apps for allergy sufferers may be created in the future to assist them in adhering to daily maintenance OIT and efficiently recording related adverse events for more efficient contact with the medical team. Virtual and augmented reality technologies have been useful in lowering fear and anxiety during tense operations like dental surgery [20] (Figure 1).



Figure 1. In the last few decades, we have made great strides in our understanding of the molecular mechanisms underlying food allergy. These have led to novel diagnostics, prevention strategies, and therapies.

CONCLUSIONS

The pathophysiological mechanism of allergic illnesses is significantly influenced by histamine, and an essential approach to studying anti-allergic medications is to examine the histamine's antagonistic action. Most anti-allergic medications utilized in clinical settings were H1 receptor antagonists. This

article discusses the key elements of the design, synthesis, and biological activity of numerous novel compounds while primarily reviewing the research development on allergic reactions with histamine H1 receptor antagonists. In terms of their chemical structural design, these novel H1 receptor antagonists are primarily produced by refining the structures of previously commercially available medications or described compounds with antiallergic activity. These molecules have unique structures, and in the future, lead compounds for the construction of H1 receptor antagonists will likely optimize the architectures of natural products. Most synthetic pathways use traditional solvent reactions to create target molecules during the synthesis process. These synthetic approaches have low operating costs, gentle reaction conditions, cheap reagents, and a decent overall yield, all of which will lay a solid platform for industrialization in the future. Nevertheless, many synthetic pathways require more than one catalyst, precious metals, or an excessively long reaction time. Researchers should prioritize contemporary synthesis techniques.

REFERENCES

1. M. Savouré, J. Bousquet, J. J. K. Jaakkola, M. S. Jaakkola, B. Jacquemin, R. Nadif, Worldwide prevalence of rhinitis in adults: A review of definitions and temporal evolution. *Clin. Transl. Allergy* **12**, e12130 (2022).
2. Bai X., Chai Y., Shi W., Li Y., Zhang T., Liu P. (2020). *Lonicera japonica* polysaccharides attenuate ovalbumin-induced allergic rhinitis by regulation of Th17 cells in BALB/c mice. *J. Funct. Foods* 65, 103758. 10.1016/j.jff.2019.103758
3. Bui T. T., Fan Y., Piao C. H., Nguyen T. V., Shin D.-u., Jung S. Y., et al. (2020). *Piper nigrum* extract improves OVA-induced nasal epithelial barrier dysfunction via activating Nrf2/HO-1 signaling. *Cell Immunol.* 351, 104035. 10.1016/j.cellimm.2019.104035
4. Cavalcanti R. F. P., Gadelha F. A. A. F., de Jesus T. G., Cavalcante-Silva L. H. A., Paiva Ferreira L. K. D., Paiva Ferreira L. A. M., et al. (2020). Warifteine and methylwarifteine inhibited the type 2 immune response on combined allergic rhinitis and asthma syndrome (CARAS) experimental model through NF-κB pathway. *Int. Immunopharmacol.* 85, 106616. 10.1016/j.intimp.2020.106616.
5. Jin C., Ye K., Luan H., Liu L., Zhang R., Yang S., et al. (2020). Tussilagone inhibits allergic responses in OVA-induced allergic rhinitis Guinea pigs and IgE-stimulated RBL-2H3 cells. *Fitoterapia* 144, 1–7. 10.1016/j.fitote.2020.104496
6. Lou H., Wang X., Wei Q., Zhao C., Xing Z., Zhang Q., et al. (2020). *Artemisia annua* sublingual immunotherapy for seasonal allergic rhinitis: a multicenter, randomized trial. *World Allergy Organ. J.* 13, 100458. 10.1016/j.waojou.2020.100458
7. Piao C. H., Fan Y. J., Nguyen T. V., Song C. H., Chai O. H. (2020). Mangiferin alleviates ovalbumin-induced allergic rhinitis via Nrf2/HO-1/NF-κB signaling pathways. *Int. J. Mol. Sci.* 21, 1–12. 10.3390/ijms21103415
8. Saito S., Takagi H., Wakasa Y., Ozawa K., Takaiwa F. (2020). Safety and efficacy of rice seed-based oral allergy vaccine for Japanese cedar pollinosis in Japanese monkeys. *Mol. Immunol.* 125, 63–69. 10.1016/j.molimm.2020.06.019
9. Sheibani V., Mandegary A., Vazifekhahan E., Kasbzade Z., Asadi A., Sharififar F. (2019). *Zataria multiflora* Boiss. extract improves spatial memory and learning capacity in scopolamine-induced amnesic rats. *Avicenna J. Phytomedicine* 9, 587–596. 10.22038/AJP.2019.13540
10. Shin S. -H., Ye M. -K., Lee D. -W., Che M. -H. (2020). Immunomodulative effects of *Chamaecyparis obtusa* essential oil in mouse model of allergic rhinitis. *Molecules* 25, 4517. 10.3390/molecules25194517
11. Zhang Y., Kang H. (2020). Protective effect of *Asarum sieboldii* essential oil on ovalbumin induced allergic rhinitis in rat. *Biosci. Rep.* 40, 1–9. 10.1042/bsr20191370
12. Zhang Y., Zhang L. (2019). Increasing prevalence of allergic rhinitis in China. *Allergy Asthma Immunol. Res.* 11, 156–169. 10.4168/aair.2019.11.2.156
13. Lou H., Huang Y., Ouyang Y. Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: a randomized controlled trial. *Allergy.* 2020**;75**:2026–2036. doi: 10.1111/all.14218.

14. Li Y, An Y, Hao Y, Zhang L, Ouyang Y. Prevalence of sensitization to specific allergens in allergic patients in Beijing, China: a 7-year retrospective stud*y. Asian Pac J. Allergy Immunol* 2021. Epub ahead of print.
15. Lou H, Wang X, Wei Q, Zhao C, Xing Z, Zhang Q, et al. Artemisia annua sublingual immunotherapy for seasonal allergic rhinitis: a multicenter, randomized trial. *World Allergy Organ J.* 2020 Sep 8;13(9):100458.
16. Lou H, Huang Y, Ouyang Y, Zhang Y, Xi L, Chu X, et al. Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: a randomized controlled trial. *Allergy* 2020 Aug;75(8):2026–36.
17. Ansotegui IJ, Melioli G, Canonica GW, Caraballo L, Villa E, Ebisawa M, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. *World Allergy Organ J.* 020 Feb 25;13(2):100080.
18. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis (2022, revision). Chin J Otorhinolaryngol Head Neck Surg, 2022,57(02):106–129
19. Deng ZY, Liu XJ, Sa RN et al (2021) Epidemiological investigation of allergic rhinitis in central cities and countrysides of Inner Mongolia region. Chin J Otorhinolaryngol Head Neck Surg 56(06):635–642
20. Yang J, Shen Z, Liu L et al (2022) Clinical efficacy and safety of *Artesimia annua*-sublingual immunotherapy in seasonal allergic rhinitis patients based on different intervention time. Int Arch Allergy Immunol 183(8):852–859

